Who
Jeffrey B. Kindler
Director
Company insider
Files Form 4 as: Director, Precigen; Director, Praxis Precision Medicines; Director, Terns Pharmaceuticals; Director, Perrigo Company; Director, Ppd; Executive Chairman, vTv Therapeutics; Director, SIGA Technologies; Director, Chipotle Mexican Grill.
In numbers
- Trades disclosed
- 331
- Buys
- 4
- Sells
- 7
- Bought
- $1.6M
- Sold
- $5.0M
- Companies
- 9
- Companies where not an officer
- 7
- First trade
- 30 Dec 2005
- Last trade
- 26 Aug 2026
- Last filed
- 28 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 26 Aug 2026filed 28 Aug 2026 | PGEN PrecigenBiotechnology | SEC FORM 4 Sold | $1.4M185,000 at $7.44 | filing |
| 26 Aug 2026filed 28 Aug 2026 | PGEN PrecigenBiotechnology | SEC FORM 4 Sold | $1.4M185,000 at $7.44 | filing |
| 10 Jun 2026filed 12 Jun 2026 | PRAX Praxis Precision MedicinesBiotechnology | SEC FORM 4 Code A | —1,371 at $0.00 | filing |
| 10 Jun 2026filed 12 Jun 2026 | PRAX Praxis Precision Medicinesoption or derivative · Biotechnology | SEC FORM 4 Code A | —648 at $0.00 | filing |
| 10 Jun 2026filed 12 Jun 2026 | PRAX Praxis Precision Medicinesoption or derivative · Biotechnology | SEC FORM 4 Code A | —648 at $0.00 | filing |
| 10 Jun 2026filed 12 Jun 2026 | PRAX Praxis Precision MedicinesBiotechnology | SEC FORM 4 Code A | —1,371 at $0.00 | filing |
| 5 May 2026filed 5 May 2026 | Terns Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | —32,000 | filing |
| 5 May 2026filed 5 May 2026 | Terns Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | —45,000 | filing |
| 5 May 2026filed 5 May 2026 | Terns Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | —10,657 | filing |
| 5 May 2026filed 5 May 2026 | Terns Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —32,000 | filing |
| 5 May 2026filed 5 May 2026 | Terns Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —45,000 | filing |
| 5 May 2026filed 5 May 2026 | Terns Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —10,657 | filing |
| 5 May 2026filed 5 May 2026 | Terns Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —4,676 | filing |
| 5 May 2026filed 5 May 2026 | Terns Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —32,000 | filing |
| 5 May 2026filed 5 May 2026 | Terns Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —28,475 | filing |
| 5 May 2026filed 5 May 2026 | Terns Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —22,000 | filing |
| 5 May 2026filed 5 May 2026 | Terns Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —32,000 | filing |
| 5 May 2026filed 5 May 2026 | Terns Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —1,697 | filing |
| 5 May 2026filed 5 May 2026 | Terns Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | —4,676 | filing |
| 5 May 2026filed 5 May 2026 | Terns Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | —32,000 | filing |
News
No headline names them, or the companies they trade most, lately.